



## Epidemiology, Vaccinology and Surveillance of COVID-19

Guest Editors:

### Prof. Dr. Min Liu

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing 100191, China

### Dr. Jue Liu

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China

Deadline for manuscript submissions:

**closed (30 June 2024)**

### Message from the Guest Editors

Dear Colleagues,

At present, COVID-19 is still a global pandemic, and SARS-CoV-2 is constantly evolving and mutating, producing variants with different transmissibility and virulence. The rapid spread of COVID-19 causes enormous impacts on social, economic, and healthcare systems in the world. Effective treatments to block the spread of COVID-19 have not been developed yet, so countries implement a series of nontreatment interventions, such as social distancing, isolation, face masks, and quarantine, to reduce its rapid transmission. Therefore, we would like to encourage the presentation to this Special Issue of the molecular characterization of different SARS-CoV-2 variants and the epidemiological characterization of the COVID-19 caused by them. Given that the COVID-19 vaccine can effectively reduce the infection rate and severity rate of COVID-19, topics concerning vaccine effectiveness, safety, willingness to vaccinate, and hesitancy of vaccinating against COVID-19 will also be welcome. Adding new information on these topics could provide a better understanding of the pathogenesis of COVID-19 and help design new surveillance and prevention strategies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)